This pathophysiology diagram illustrates the link between the altered secretory profile of epicardial adipose tissue (EAT) and the pathogenesis of acute coronary syndrome (ACS). The left panel lists inflammatory cytokines and adipokines secreted by EAT, including IL-1β, IL-6, TNF-α, MCP-1, Resistin, FABP4, and Leptin, alongside anti-inflammatory factors like Adiponectin and Omentin-1. An arrow indicates how these secretions promote inflammation, immune cell recruitment, thrombosis, lipotoxicity, and increased endothelial permeability. The right panel depicts the progression of coronary artery disease: starting from an artery with a stable atherosclerotic plaque, the process advances through plaque rupture or erosion to thrombus formation. This culminates in two clinical outcomes: complete coronary artery occlusion, leading to ST-elevation myocardial infarction (STEMI), and partial occlusion, leading to unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI). The diagram utilizes cross-sectional anatomical illustrations of coronary arteries to show varying degrees of luminal narrowing and thrombus size.

A multi-panel medical infographic and diagnostic imaging collage illustrating non-invasive coronary imaging modalities. The central feature is a Venn diagram highlighting three clinical objectives: coronary stenosis assessment (yellow), atherosclerotic burden quantification (blue), and plaque vulnerability identification (green). Overlapping regions link these objectives to clinical scenarios such as suspected stable angina pectoris, suspected acute coronary syndrome, and asymptomatic risk stratification. Surrounding the diagram are four diagnostic images: (A) a computed tomography angiography (CTA) showing coronary vessel morphology; (B) a coronary artery calcium (CAC) scan highlighting high-density calcified plaques; (C) a T1-weighted magnetic resonance coronary angiography showing potential intracoronary thrombus or intraplaque hemorrhage; and (D) a positron emission tomography (PET) scan utilizing radioactive tracers to map metabolic markers of plaque instability, indicated by focal orange/red hotspots. This educational visual demonstrates the complementary roles of CT, MRI, and PET in cardiology for evaluating ischemic heart disease and vascular health.

Summary : This diagram classifies acute coronary syndromes (ACS) based on clinical presentation, ECG findings, and troponin levels, distinguishing between unstable angina, non-ST-segment elevation, and ST-segment elevation myocardial infarction, and further subdividing by underlying pathophysiology. flowchart: # Main Categories : • Acute coronary syndromes (top-level box). • Two main branches: Unstable angina and Acute myocardial infarction (AMI). # Subcategories : • Under Acute myocardial infarction (AMI): – NSTEACS (Non-ST-segment elevation acute coronary syndromes) – STEACS* (ST-segment elevation acute coronary syndromes) • Under NSTEACS: – Unstable angina – NSTEMI (Non-ST-segment elevation myocardial infarction) • Under STEACS*: – STEMI (ST-segment elevation myocardial infarction) – ACOMI# (AMI due to significant epicardial coronary occlusion) # Pathophysiological Mechanisms : • AMI due to acute coronary occlusion: – Plaque rupture/erosion with thrombus – SCAD (Spontaneous coronary artery dissection) – Coronary embolism – Vasospasm or microvascular dysfunction • AMI due to oxygen supply/demand mismatch without acute coronary occlusion # Troponin Gradient : • A horizontal arrow at the bottom labeled from "Non-elevated troponin" (left, green) to "Increasing troponin" (right, red), indicating the spectrum of troponin elevation across the syndromes. # Layout : • Hierarchical, left-to-right and top-to-bottom arrangement. • Boxes are nested to show relationships (e.g., NSTEMI is under both NSTEACS and AMI). • Pathophysiological mechanisms are shown as underlying causes for AMI. Analysis : • The diagram visually organizes ACS into unstable angina and AMI, with further division by ECG findings (ST-segment elevation or not) and underlying cause (occlusion vs. supply/demand mismatch). • Troponin levels increase from unstable angina (non-elevated) to STEMI/ACOMI (markedly elevated). • The flowchart clarifies that not all AMI is due to acute coronary occlusion, and highlights the importance of both clinical and biochemical markers in diagnosis.

This composite figure demonstrates diagnostic imaging of the coronary arteries in a patient with unstable angina pectoris (UAP). Figure A is a coronary angiography (CA) frame showing the left coronary system, with a white arrowhead identifying a hazy, eccentric plaque at the ostium of the left anterior descending (LAD) artery. Figure B and C provide high-resolution intravascular imaging using optical coherence tomography (OCT). Figure B displays a longitudinal reconstructed view of the LAD plaque over a 50mm segment. Figure C shows a cross-sectional OCT view of the ostial LAD, revealing a plaque with an area stenosis of 38%. The image highlights plaque erosion with superficial calcific plaque (PE-SCP), marked by white stars, which is overlaid by white thrombi, indicated by white arrows. An OCT imaging catheter is centered within the vessel lumen. This set of images illustrates the clinical utility of combining luminal angiography with intravascular OCT to characterize vulnerable plaque morphology, such as calcific erosion and associated thrombosis, in acute coronary syndromes.

A medical infographic and signaling pathway diagram illustrating the clinical uses and mechanism of phosphodiesterase 5 inhibitors (PDE5-Is). The central panel depicts the cellular NO/cGMP pathway: Nitric Oxide (NO) stimulates soluble guanylyl cyclase (sGC) to convert GTP into cGMP. cGMP then activates Protein Kinase G (PKG), leading to decreased intracellular calcium [Ca2+] and subsequent smooth muscle relaxation. PDE5-Is are shown inhibiting the degradation of cGMP into inactive 5' GMP. The diagram branches into three primary clinical applications: 1) Lower Urinary Tract (LUT), showing relaxation of prostate/bladder muscles and increased oxygen perfusion for treating LUTS secondary to Benign Prostatic Hyperplasia (BPH); 2) Penis, illustrating increased arterial inflow resulting in erection for treating Erectile Dysfunction; and 3) Lungs, detailing vasodilation and cellular changes (decreased DNA synthesis/proliferation, increased apoptosis) in pulmonary artery smooth cells for treating Pulmonary Arterial Hypertension (PAH). The illustration uses anatomical icons and flow arrows to connect molecular signaling to systemic physiological outcomes.

This pathophysiology diagram illustrates the biochemical mechanism by which Cinnamomum osmophloeum hydrosol influences erectile function through multi-pathway enzymatic inhibition within endothelial and vascular smooth muscle cells (VSMCs). The flowchart highlights four primary inhibitory targets: AChE (acetylcholinesterase), which breaks down acetylcholine into acetate and choline; ARG2 (arginase 2), which competes for arginine to produce L-ornithine and urea; ACE (angiotensin-converting enzyme), which converts Angiotensin I to the vasoconstrictor Angiotensin II; and PDE5 (phosphodiesterase type 5), which degrades cGMP. The diagram depicts the positive signaling cascade where acetylcholine activates muscarinic receptors (mAChR), increasing calcium and calmodulin (CAM) to activate phosphorylated eNOS (eNOS-P). This results in nitric oxide (NO) production, which diffuses to VSMCs to stimulate soluble guanylate cyclase (sGC). The sGC converts GTP to cGMP, activating protein kinase G (PKG) and leading to smooth muscle relaxation and vasodilation. Two novel PDE5 inhibitor isomers (trans- and cis-phenyloxetan-3-ol) are shown with their respective IC50 values (4.37 µM and 3.40 µM), demonstrating their structural role in maintaining cGMP levels to treat erectile dysfunction.

This pathophysiology diagram illustrates the impact of oxidative stress (OS) and nitric oxide synthase (NOS) on the blood vascular system, contrasting healthy and dysfunctional endothelial pathways. The 'Healthy Endothelium' branch (left) shows stimuli activating the alpha/beta/gamma complex, Akt, and eNOS, leading to nitric oxide (NO) production via SIRT1 mediation. This triggers the sGC-cGMP pathway in smooth muscle cells (SMC), resulting in relaxation, vasodilation, anti-proliferation, anti-inflammation, and thrombolysis. In contrast, the 'Dysfunctional Endothelium' branch (right) shows how risk factors like dyslipidemia, obesity, and diabetes, alongside OS and inflammation, inhibit eNOS activity despite L-Arginine availability. This lack of NO leads to vasoconstriction, thrombosis, and atherosclerosis. The diagram includes a cross-sectional illustration of a narrowed artery showing the progression of cardiovascular disease (CVD). Supplemental boxes list the three isoforms of NOS (eNOS/NOS3, nNOS/NOS1, and iNOS/NOS2) and summarize the effects of OS, including inflammation and vascular remodeling. This visual serves as an educational tool for understanding molecular mechanisms of hypertension and endothelial health.

This Comparison Chart displays two side-by-side Doppler echocardiography panels illustrating the hemodynamic effects of beta-blocker therapy on intraventricular gradients (IVG). Each panel contains a B-mode ultrasound image at the top (parasternal long-axis view) and a continuous-wave Doppler spectral waveform below. The left panel ('Without beta blocker') shows a high-velocity, late-systolic peaking envelope reaching a peak velocity (Vel) of 526 cm/s and a pressure gradient (PG) of 110 mmHg, characteristic of dynamic left ventricular outflow tract obstruction. The recorded heart rate is 160 BPM. The right panel ('With beta blocker') demonstrates a significant reduction in the Doppler envelope's depth and intensity, reflecting a lower flow velocity and decreased pressure gradient, with a corresponding heart rate reduction to 121 BPM. This comparison illustrates the clinical use of beta-blockers to manage exertional intraventricular gradients and systolic anterior motion (SAM) of the mitral valve by reducing contractility and heart rate. The educational focus is on pharmacological intervention for dynamic cardiac obstruction and the interpretation of Doppler spectral displays in sports cardiology and hemodynamics.

<table> <tr> <th></th> <th>Population</th> <th>Initial Dose</th> </tr> <tr> <td></td> <td>Maximally tolerated beta-blocker dose with persistent resting heart rate ≥70 beats/min</td> <td>5 mg twice daily with meals</td> </tr> <tr> <td></td> <td>History of conduction defects<br>Age ≥75 y</td> <td>2.5 mg twice daily with meals</td> </tr> </table>

This Comparison Chart displays a 12-lead electrocardiogram (ECG) series from a patient with Long QT Syndrome Type 2 (LQT2), demonstrating the pharmacological effects of different agents on cardiac repolarization. The image is divided into four panels (A-D) representing sequential clinical states. Panel A (Baseline) shows a heart rate (HR) of 73 bpm and a markedly prolonged QTc of 538 ms, with notched T-waves characteristic of LQT2. Panel B (Two days after oral nadolol) illustrates drug-induced bradycardia (HR 47 bpm) and further QTc prolongation to 590 ms, highlighting the risk of beta-blocker-induced bradycardia in certain LQT2 phenotypes. Panel C (After lidocaine i.v.) shows a dramatic shortening of the QTc to 436 ms, demonstrating the efficacy of Class Ib antiarrhythmic agents in blocking late sodium currents (INaL). Panel D (After oral mexiletine) confirms a sustained near-normal QTc of 445 ms at a HR of 67 bpm. This visual sequence serves as an educational tool for identifying LQT2 morphology, understanding the Bazett-corrected QT interval relationship with heart rate, and evaluating the paradoxical response to beta-blockers versus the therapeutic benefit of sodium channel blockers.